Dr Reddy’s Laboratories has announced the launch of Obeda®, India’s first generic injectable semaglutide approved by the Drugs Controller General of India for the treatment of type 2 diabetes. The launch marks a significant step in expanding access to GLP-1 receptor agonist therapies in India, where the burden of diabetes continues to rise sharply. With over 100 million adults living with diabetes and millions more at risk, there is increasing demand for effective and accessible treatment options.
Obeda® is available in 2 mg and 4 mg strengths and is administered once weekly using a pre-filled, disposable pen designed for subcutaneous use. The therapy is priced at ₹4,200 per month, aiming to make advanced diabetes treatment more accessible to patients across the country.
Clinical studies demonstrated that Obeda® delivers efficacy and safety comparable to the reference product. The treatment showed similar outcomes in glycaemic control, including reductions in HbA1c levels, as well as improvements in fasting and post-meal glucose levels. Additional human factors studies confirmed that the delivery device is user-friendly and comparable in performance to existing options.
MV Ramana, Chief Executive Officer for Branded Markets at Dr Reddy’s, said the launch reflects the company’s commitment to expanding access to advanced therapies. He emphasized that addressing India’s growing diabetes burden requires both innovation and affordability.
To support patients, the company has introduced SemaKare™, a comprehensive support programme that includes onboarding assistance, injection training, tele-support, and adherence monitoring through a digital platform. Dr Reddy’s is also working to establish metabolic care centers across India to improve diagnosis, treatment, and patient education. In addition, the company plans to integrate nutritional support solutions through its joint venture with Nestlé Health Science, addressing broader patient needs associated with metabolic conditions.
Dr Reddy’s, founded in 1984 and headquartered in Hyderabad, is a global pharmaceutical company committed to expanding access to affordable and innovative medicines. Guided by its purpose, “Good Health Can’t Wait,” the company offers APIs, generics, branded generics, biosimilars, and OTC products across the U.S., India, Russia & CIS, China, Brazil, and Europe. As one of the early Indian adopters of ESG principles, Dr. Reddy’s continues to invest in future-focused, science-driven, and socially responsible operations.
With this launch, Dr Reddy’s strengthens its diabetes portfolio and reinforces its focus on improving long-term health outcomes. The company continues to invest in science-driven solutions aimed at addressing chronic diseases and enhancing patient access to high-quality care.
